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An Important Role of VEGF-C in Promoting
Lymphedema Development
Epameinondas Gousopoulos1, Steven T. Proulx1, Samia B. Bachmann1, Lothar C. Dieterich1,
Jeannette Scholl1, Sinem Karaman1,2, Roberta Bianchi1 and Michael Detmar1
Secondary lymphedema is a common complication after cancer treatment, but the pathomechanisms under-
lying the disease remain unclear. Using a mouse tail lymphedema model, we found an increase in local and
systemic levels of the lymphangiogenic factor vascular endothelial growth factor (VEGF)-C and identified
CD68þ macrophages as a cellular source. Surprisingly, overexpression of VEGF-C in a transgenic mouse model
led to aggravation of lymphedema with increased immune cell infiltration and vascular leakage compared with
wild-type littermates. Conversely, blockage of VEGF-C by overexpression of soluble VEGF receptor-3 reduced
edema development, diminishing inflammation and blood vascular leakage. Similar findings were obtained in a
hind limb lymph node excision lymphedema model. Flow cytometry analyses and immunofluorescence
stainings in lymphedematic tissue showed that VEGF receptor-3 expression was restricted to lymphatic
endothelial cells. Our data suggest that endogenous VEGF-C causes blood vascular leakage and fluid influx into
the tissue, thus actively contributing to edema formation. These data may provide the basis for future clinical
therapeutic approaches.
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INTRODUCTION
Lymphedema constitutes the cardinal manifestation of
lymphatic malfunction, characterized by lymphatic stasis,
profound inflammation, and fibroadipose tissue accumula-
tion (Rockson, 2000). It commonly occurs upon lymphatic
injury due to surgical cancer treatment or radiotherapy, with
breast cancer survivors representing most patients affected
(Cormier et al., 2010; Rockson and Rivera, 2008). Despite the
large number of patients developing lymphedema, no cura-
tive treatment exists so far, and the knowledge about the
pathomechanisms that govern the development of lymphe-
dema is rather limited and incomplete.
There is increasing evidence suggesting that lymphedema
development is a multistep process, where lymphatic injury
is the trigger of a sequence of pathological consequences
(Rockson, 2008). Lymphedema develops in only a fraction of
cancer survivors (up to 30%) (Warren et al., 2007) and mostly
in a delayed fashion, indicating that secondary events might
be requisite for the development of the disease. Lymphedema
may even appear after seemingly minor injuries of the
lymphatic vasculature (e.g., lymph node biopsy), indicating
that a simple “stopcock” mechanism, due to obstruction of
lymphatic fluid transport, fails to explain many clinical as-
pects of lymphedema pathology (Stanton et al., 2009).
Edema, inflammation, and fibroadipose tissue deposition
represent the best characterized features of lymphedema
pathophysiology, but the contribution of other cellular com-
ponents to the development of the disease has not been
extensively studied. Stanton and colleagues (Stanton et al.,
2009) reported that blood capillary angiogenesis occurs in
the skin of swollen lymphedematic arms, whereas lymphatic
flow and lymphatic capillary width were increased in the
contralateral arm in patients with breast cancer-related lym-
phedema (BCRL). Moreover, global abnormalities in
lymphatic function were detected in patients who developed
BCRL, as were higher pumping pressures in women destined
to develop BCRL. These findings indicate factors that pre-
dispose patients to lymphedema development or systemic
changes after surgery or other treatments (Bains et al., 2015;
Cintolesi et al., 2016).
Recently, a systemic increase in vascular endothelial
growth factor (VEGF)-C levels was reported in BCRL patients,
associated with increased forearm capillary filtration capacity
(Jensen et al., 2015). Even though adenoviral delivery of
VEGF-C had beneficial effects in lymph node engraftment
and formation of new lymphatic vessels in animal models
(Tammela et al., 2007), the relevance of VEGF-C for lym-
phedema pathogenesis has remained unknown (Visuri et al.,
2015). In particular, it remains unclear whether endoge-
nously produced VEGF-C plays a detrimental or a beneficial
role in the process of lymphedema development.
In this study, we used an established mouse tail model of
secondary surgical lymphedema (Gousopoulos et al., 2016b)
and genetic mouse models for VEGF-C gain and loss of
function to investigate the potential role of VEGF-C in the
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pathophysiology of the disease. We found increased levels of
VEGF-C both locally and systemically during lymphedema
development. Overexpression of VEGF-C in the skin of ker-
atin (K) 14eVEGF-C transgenic mice surprisingly aggravated
lymphedema development, leading to increased immune cell
infiltration and increased blood vascular leakage. Conversely,
neutralization of VEGF-C/-D in K14-sVEGF receptor
(VEGFR)-3-Ig transgenic mice led to the opposite results. The
morphological and histopathological findings were further
confirmed in gain- and loss-of-function studies in the hind
limb mouse lymphedema model. We found that VEGFR3
expression was confined to lymphatic endothelial cells in
lymphedema, indicating that VEGF-C promotes vascular
leakage through VEGFR2. Together, these data point to a
critical, active role of VEGF-C in promoting the pathogenesis
of lymphedema.
RESULTS
VEGF-C increases locally and systemically during
lymphedema development and is produced by CD68D
macrophages
To investigate the dynamics of expression of VEGFs during
the course of lymphedema development, we surgically
induced secondary lymphedema in the tails of wild-type
mice and analyzed the mRNA expression of VEGF-A,
VEGF-C, and VEGF-D in tail skin lysates at different time
points. A significant increase in VEGF-C expression was
detected 2 weeks (P < 0.05) and 6 weeks after surgery (P <
0.01) (Figure 1a). There was a significant up-regulation of
VEGF-C after 6 weeks (P < 0.05). In contrast, VEGF-A
expression levels were decreased 2 weeks after surgery (P
< 0.01) (Figure 1a).
We next investigated whether this increase in VEGF-C/-D
mRNA would result in elevated systemic levels of VEGF-C
or VEGF-D during the course of lymphedema. VEGF-C and
VEGF-D protein levels were measured by ELISA in mouse
serum, and a systemic increase of VEGF-C was detected 6
weeks after surgery (P < 0.001), whereas the levels of VEGF-
D remained largely unchanged during the course of lym-
phedema development (Figure 1b).
Because increased levels of VEGF-C were detected both
locally and systemically upon lymphedema development in
our mouse model, we next aimed to determine the cellular
source of VEGF-C. To this end, we subjected VEGF-C-LacZ
reporter mice to surgical lymphedema induction and evalu-
ated X-Gal staining in the lymphedematic tail tissue 2 weeks
later. Using this approach, we identified CD68þmacrophages
to be the major source of VEGF-C expression in this model
(Figure 1c). Furthermore, we isolated CD11bþ/F4/80þ and
CD11bþ/F4/80e cells from control (unoperated) and lymphe-
dematicmouse tails. Quantitative PCR analysis of VEGF-C and
VEGF-D showed that VEGF-C expression was significantly
increased in CD11bþF4/80þ macrophages (P < 0.05) upon
induction of lymphedema. Similarly, VEGF-D expression
appeared to be increased in CD11bþF4/80þ macrophages as
well, without reaching statistical significance (Figure 1d).
Skin-specific VEGF-C overexpression exacerbates
lymphedema
Because lymphedema induced local and systemic increases
of VEGF-C, we next evaluated whether VEGF-C might play
a beneficial or detrimental role in lymphedema. K14eVEGF-
C mice, producing human VEGF-C in epidermal keratino-
cytes under control of the K14 promoter, and their wild-type
littermates had surgery and were monitored for 2 weeks. Tail
volume measurements indicated increased edema in the
transgenic versus wild-type mice already at 1 week after
surgery (P < 0.01), which remained significantly elevated 2
weeks after the operation as well (P < 0.01) (Figure 2a).
Evaluation of the change of tail volume showed a 66.07%
greater volume increase in the K14eVEGF-C transgenic mice
than in the wild-type mice at 2 weeks after the operation,
leading to significantly more edematic tails (Figure 2a, 2b).
To further validate our findings, we used an additional
acute lymphedema model, in which edema was induced by
removing the popliteal lymph node (Frueh et al., 2016). Paw
thickness measurements showed significantly increased
edema in K14eVEGF-C transgenic mice (P < 0.05, P <
0.001) at two timepoints after surgery (see Supplementary
Figure S1a, S1b online).
Lymphangiogenesis and inflammation are characteristic
features of lymphedema development (Rutkowski et al.,
2006). We found that in tail sections of K14eVEGF-C mice
that did not have surgery, a larger fraction of the tissue was
covered by LYVE-1þ lymphatic vessels than in wild-type mice
(P < 0.01), whereas no changes were detected in the area
covered by Meca32þ blood vessels (Figure 2c). Two weeks
after lymphedema induction, there was a 2- to 3-fold increase
of lymphatic vessel coverage compared with untreated con-
trols in both groups, with no major differences between
transgenic and wild-type mice. Blood vessel coverage was
slightly increased as well after 2 weeks in both groups
(Figure 2c). In the mouse hind limb lymphedema model,
increased lymphatic vessel area coverage was observed in
K14eVEGF-C transgenic mice after lymphedema induction,
whereas the blood vascular coverage remain unchanged (see
Supplementary Figure S1c, S1d). Because CD68þ macro-
phages were identified as producers of VEGF-C during lym-
phedema development, we next analyzed the CD68þ cell
infiltrate. No significant differences in the CD68-positive
tissue area were found between wild-type and transgenic
mice, even though a strong trend toward a higher macro-
phage density was observed in the hind limb model
(Figure 2d, and see Supplementary Figure S2a, S2b online).
VEGF-C overexpression results in increased blood vascular
leakage and altered immune cell infiltration
The increased edema formation observed in K14eVEGF-C
mice might be due to changes in the inflammatory cell
infiltrate and/or to increased blood vascular leakage. To
evaluate the immune cell infiltrate, flow cytometry analysis
was performed assessing the major immune populations
within the lymphedematic tissue. At 2 weeks after surgery,
there was a significant increase of CD45þ (P < 0.01),
CD11bþ (P < 0.05), and CD11cþ/F4/80þ cells (P < 0.05)
compared with the wild-type mice (Figure 3a). Similarly,
immunohistological analysis showed an increased immune
cell infiltration in K14eVEGF-C transgenic mice in the hind
limb model (see Supplementary Figure S2a, S2b).
We next investigated the effects of increased VEGF-C
levels on lymphatic vascular transport function and blood
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vascular leakage by noninvasive dynamic near-infrared im-
aging. To examine the lymphatic vascular transport function
2 weeks after surgery, a PEGylated near-infrared dye (20kDa
PEG-IRDye800), known to be taken up selectively by the
lymphatic vasculature (Proulx et al., 2013b), was slowly
perfused into the tip of the tail, and its transport to the edge of
the excised area was monitored. Quantification of the dye 1.5
cm distal to the surgical excision area showed decreased
transport of the dye in K14eVEGF-C transgenic mice (P <
0.05), suggesting impaired lymphatic vascular transport
function after exacerbated lymphedema development (see
Supplementary Figure S3a online).
Blood vascular leakage was studied distal to the surgical
excision margin 1 day after the operation and before devel-
opment of measurable edema, to evaluate the contribution of
vessel leakage to edema formation. At this time point only
increased VEGF-C and VEGF-D expression was noted,
whereas VEGF-A expression remained unchanged (see
Supplementary Figure S3bed). After intravenous injection of
a 20-kDa PEG-IRDye800 near-infrared tracer (Proulx et al.,
2013a), transgenic mice exhibited a 2.44-fold higher
leakage rate compared with the wild-type mice (P < 0.05), as
determined by the increase of extravasated tracer signal in the
tissue (Figure 3b). This indicates that VEGF-C overexpression
increases blood vessel leakiness, thus leading to increased
edema formation.
Previously, VEGF-C has been implicated in the regulation
of blood pressure, which could potentially affect vascular
leakage indirectly (Machnik et al., 2009). However, both
systolic and diastolic blood pressures were not different be-
tween the two groups, indicating that blood pressure changes
are not involved in the observed vascular leakage (see
Supplementary Figure S4a online).
Reduced lymphedema development in K14esVEGFR3eIg
transgenic mice
Because overexpression of VEGF-C aggravated lymphedema
development, we next investigated whether blockade of
VEGF-C might reduce lymphedema. To this end, we studied
K14-sVEGFR3-Ig mice that express a soluble form of
Figure 1. Local and systemic increase
of VEGF-C during lymphedema
development. (a) Expression levels of
VEGF-C mRNA in tail skin
significantly increased 2 weeks after
surgery and remained elevated 6
weeks after surgery. VEGF-D mRNA
expression was significantly increased
after 6 weeks. VEGF-A levels were
decreased 2 weeks after surgery. (b)
ELISA of mouse serum showed
increased systemic levels of VEGF-C
at 6 weeks after surgery, but VEGF-D
levels remained unchanged (n ¼ 5,
one-way analysis of variance with
Dunnett post hoc multiple
comparison test). (c) Double staining
for X-gal (VEGF-C-LacZ) and CD68 2
weeks after surgery indicated that
CD68þ macrophages constitute a
major source of VEGF-C during
lymphedema development. (d)
Increased VEGF-C mRNA expression
was identified only on isolated
CD11bþ/F4/80þ cells 2 weeks after
surgery but not on CD11bþ/F4/80e
cells. Scale bar ¼ 50 mm. *P < 0.05,
**P < 0.01, ***P < 0.001. Ctrl.,
control; expr., expression; Rel.,
relative; VEGF, vascular endothelial
growth factor; w, week.
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VEGFR3 under control of the K14 promoter, thereby scav-
enging the VEGFR3 ligands VEGF-C and VEGF-D in the
skin. K14-sVEGFR3-Ig mice that did not have surgery
exhibited a mild primary lymphedema in the tail skin (not
statistically significant) (Figure 4a) and a more pronounced
edema in the paw (P < 0.001) (see Supplementary
Figure S5a online). At 1 and 2 weeks after surgery, the tail
volume was comparably increased in wild-type and trans-
genic mice (Figure 4a). Because the K14-sVEGFR3-Ig mice
exhibited a higher baseline tail volume, we calculated the
volume change after surgery and found a significantly lower
increase in tail volume in the transgenic mice both 1 week
(P < 0.01) and 2 weeks after surgery (P < 0.05) (Figure 4a,
4b). We further examined these observations in the mouse
hind limb lymphedema model. Paw thickness measure-
ments showed comparable changes in the wild-type and
transgenic mice upon lymph node removal. Given the
increased baseline thickness of the transgenic mice, the
percentage thickness change was significantly lower in
the transgenic group (P < 0.05, P < 0.001), further sup-
porting the results obtained in the mouse tail model (see
Supplementary Figure S5a, S5b).
Figure 2. Overexpression of VEGF-C
exacerbates lymphedema
development. (a) Evaluation of tail
volume (left) and volume change
(right) showed significantly increased
edema formation in K14-VEGF-C
transgenic (TG) mice compared with
their wild-type (WT) littermates at 2
weeks after the operation. (b)
Representative pictures of WT and
K14-VEGF-C TG mouse tails at 2
weeks after surgery. Scale bar ¼ 1 cm.
(c) TG mice without surgery (un-op)
had an expanded lymphatic network
(LYVE-1 staining, green) compared
with WT mice, without major
differences in blood vessels (Meca32
staining, red). Hoechst nuclear
staining is in blue. At 2 weeks after
induction of lymphedema, lymphatic
vessels were further expanded in both
groups, but no major differences
between WT and TG mice were found
regarding lymphatic and blood vessel
coverage. (d) Staining for CD68þ
macrophages did not show major
changes between WT and VEGF-C
overexpressing mice at the examined
time points (n ¼ 5e7 per group, one-
way analysis of variance with Tukey
post hoc multiple comparison test or
two-way analysis of variance with
Bonferroni post hoc test was used to
compare means of three or more
groups. **P < 0.01). Scale bars ¼ 200
mm. post-op, after surgery; VEGF,
vascular endothelial growth factor.
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We next evaluated the response of lymphatic and blood
vessels to VEGF-C neutralization. Untreated K14-sVEGFR3
transgenic mice had a decreased tissue area covered by
LYVE-1þ lymphatic vessels (P < 0.05) and by Meca32þ blood
vessels (P < 0.01) (Figure 4c). At 2 weeks after lymphedema
induction, transgenic mice showed no signs of vascular
expansion, resulting in significantly lower tissue coverage by
lymphatic vessels (P < 0.01) and blood vessels (P < 0.05)
compared with wild-type mice (Figure 4c). In the hind limb
lymphedema model, lymphatic coverage was also reduced in
K14-sVEGFR3-Ig mice, but no changes in the blood vascular
coverage were observed (see Supplementary Figure S5c,
S5d). This observation might be related to site-specific dif-
ferences of the skin. Quantification of the area covered by
CD68þmacrophages showed a comparable area in untreated
mice, whereas transgenic mice had a decreased infiltration
by CD68þ cells (P < 0.05) 2 weeks after surgery (Figure 4d).
Similar findings were obtained in the hind limb lymphedema
model (P < 0.01) (see Supplementary Figure S6a, S6b online).
Decreased immune cell infiltration and decreased blood
vascular leakage in K14-sVEGFR3-Ig mice
Based on the reduced infiltration by CD68þ cells observed
into the lymphedematic tail of K14-sVEGFR3-Ig transgenic
mice 2 weeks after surgery, we next performed flow cytom-
etry analyses to evaluate the immune cell infiltration in more
detail. We found a trend toward decreased numbers of
CD45þ, CD11bþ, and CD11cþ/ F4/80þ cells 2 weeks after
surgery in K14-sVEGFR3-Ig transgenic mice (Figure 5a) and
significantly reduced numbers of CD4þ cells (P < 0.05)
(Figure 5a). CD4þ cells have previously been shown to
aggravate lymphedema formation (Gousopoulos et al.,
2016a; Zampell et al., 2012b).
Evaluation of blood vascular leakage 1 day after surgery
showed a significantly decreased leakage rate of the intra-
venously injected near-infrared tracer into the tail tissue of
K14-sVEGFR3-Ig mice compared with wild-type controls (P
< 0.01) (Figure 5b).
VEGFR3 expression is restricted to lymphatic endothelial
cells in lymphedematic skin
Because overexpression of VEGF-C aggravated lymphedema,
whereas overexpression of the soluble form of VEGFR3
reduced lymphedema development and also decreased the
infiltration of CD68þ macrophages and CD4þ T cells, we
sought to identify the cell populations in tail skin that express
VEGFR3 and might thus respond to VEGF-C. To this end, we
used VEGFR3-Cre-tdTomato reporter mice that express the
fluorescent protein tdTomato in cells where the VEGFR3
promoter was active. VEGFR3-Cre-tdTomato mice had sur-
gery, and the expression of VEGFR3 was evaluated by flow
cytometry analysis on lymphatic and blood vascular endo-
thelial cells and on myeloid (CD11bþ) and T cells (CD3þ)
cells 2 weeks after surgery. tdTomato fluorescence was only
detectable in lymphatic endothelial cells (CD31þ/
podoplaninþ) but not in blood vascular endothelial cells
(CD31þ/podoplanine) or immune cells (CD45þ/CD11bþ and
CD45þ/CD3þ) (Figure 6a, 6b). Furthermore, immunofluo-
rescence double-stainings for VEGFR3 and LYVE-1, Meca-32,
or CD68 showed that VEGFR3 was exclusively present on
LYVE-1þ lymphatic vessels but not on Meca-32þ blood ves-
sels or CD68þ macrophages (Figure 6c). Because VEGF-C is
known to bind to and activate VEGFR2 in addition to
VEGFR3, these data suggest that VEGF-C may regulate blood
vessel leakage directly by activating VEGFR2 on blood vessel
endothelial cells.
DISCUSSION
Lymphedema develops in up to 30% of breast cancer survi-
vors after surgery and/or radiotherapy (Warren et al., 2007),
with lymphatic injury considered to represent the initiator of
a sequence of events that finally leads to the development of
the disease. However, the consecutive steps that lead to
chronic lymphedema, characterized by profound inflamma-
tion and fibroadipose tissue deposition, and the potential
participation of other cellular and molecular players in the
pathogenesis remain unclear.
A key finding of this study was that VEGF-C promoted
blood vascular leakage in experimental, surgically induced
lymphedema. VEGF-C expression in the lymphedematic tis-
sue was up-regulated already within 2 weeks after surgery, in
contrast to VEGF-A, arguing against a major role of VEGF-A
in lymphedema formation. These data are in line with a
recent RNA sequencing study of lymphedematic tissue
(Gousopoulos et al., 2016a). Circulating VEGF-C protein
levels were elevated at 6 weeks after surgery in mice, and the
clinical relevance of these findings is confirmed by the
Figure 3. VEGF-C overexpression led to increased immune cell infiltration and increased blood vascular leakage. (a) Flow cytometry analysis was performed to
evaluate the immune cell populations in wild-type (WT) and K14-VEGF-C transgenic (TG) mice at 2 weeks after lymphedema induction. Increased percentages
of CD45þ, CD11bþ, and CD11cþ/F4/80þ cells were noted. (b) Evaluation of the blood vascular leakage rate distal to the surgery site 1 day after the operation,
before the development of measurable edema. There was a significantly increased leakage rate of the intravenously injected 20-kDa PEG-IRDye800 near-
infrared tracer into the tail tissue of VEGF-Ceoverexpressing mice. n ¼ 6e8; Student t test, *P < 0.05. VEGF, vascular endothelial growth factor.
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elevated VEGF-C levels recently reported in serum samples of
BCRL patients (Jensen et al., 2015). Elevated systemic levels
of the potent lymphangiogenic factor VEGF-C provides a
molecular explanation for the observed increased lymph
drainage rate in the contralateral hand of BCRL patients and
for the increased lymphatic capillary width in the contralat-
eral forearm of these patients (Stanton et al., 2009).
VEGF-C is a major lymphangiogenic factor that enhances
proliferation, migration, and survival of lymphatic endothe-
lial cells (Tammela et al., 2005). Previously, it has been found
that overexpression of either VEGF-C or VEGF-D in
experimental mouse models promotes sprouting lym-
phangiogenesis and lymphatic vascular enlargement, and
indeed, profound enlargement of lymphatic vessels and
active proliferation of lymphatic endothelial cells have also
been reported in experimental models of lymphedema
(Gousopoulos et al., 2016b; Rutkowski et al., 2006; Zampell
et al., 2012b). Under certain experimental conditions, VEGF-
C and VEGF-D overexpression may also induce angiogenesis
in experimental animal models (Cao et al., 2004; Rissanen
et al., 2003; Saaristo et al., 2002a; Witzenbichler et al.,
1998). This activity is thought to be mediated by the
Figure 4. Reduced lymphedema
development in K14-sVEGFR3-Ig
transgenic mice. (a) Evaluation of tail
volume (left) and volume change
(right) showed increased tail volume
in the K14-sVEGFR3-Ig transgenic
mice without surgery and a lower
percentage increase of tail volume at 1
and 2 weeks after surgery. (b)
Representative pictures of mouse tails
of wild-type (WT) and transgenic (TG)
mice at 2 weeks after surgery. Scale
bar ¼ 1 cm. (c) Expression of VEGFR3s
led to decreased lymphatic (LYVE-1,
green) and blood vessel (Meca32, red)
density in the tail skin of transgenic
mice both before and after
lymphedema induction. Blue:
Hoechst nuclear staining. (d) Whereas
CD68þ macrophage levels were
comparable in mice without surgery
(un-op) of both genotypes, TG mice
had a decreased CD68þ cell
infiltration 2 weeks after lymphedema
surgery. n ¼ 5e7 per group, one-way
analysis of variance with Tukey post
hoc multiple comparison test or two-
way analysis of variance with
Bonferroni post hoc test was used to
compare means of three or more
groups. *P < 0.05, **P < 0.01. Scale
bars ¼ 200 mm (c and d). post-op, after
surgery; VEGFR, vascular endothelial
growth factor receptor.
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proteolytically processed mature forms of VEGF-C and VEGF-
D that have been reported to bind to the VEGFR2 expressed
on blood vessels and to increase angiogenesis and blood flow
(Anisimov et al., 2009). In this context, the recently observed
increased capillary filtration rate in the affected (Jensen et al.,
2015) and contralateral forearms (Stanton et al., 2009) of
BCRL patients, as well as the increased lymphatic pumping in
the upper limbs of patients who later develop lymphedema
(Cintolesi et al., 2016), might be explained by the elevated
circulating levels of VEGF-C.
Macrophages are a natural source of VEGF-C (Harvey and
Gordon, 2012), and this population has previously been re-
ported to strongly increase upon induction of experimental
lymphedema (Gousopoulos et al., 2016b; Ogata et al., 2016;
Zampell et al., 2012b). This is in agreement with our finding
that CD68þ macrophages infiltrated lymphedematic tissue
and were the major producers of VEGF-C, as indicated by our
studies in VEGF-C lacZ reporter mice. Furthermore, further
analysis of isolated CD11bþ/F4/80þ and CD11bþ/F4/80e cells
from control and surgically treated tails showed increased
VEGF-C expression and a trend for augmented VEGF-D
expression in the CD11bþ/F4/80þ macrophages only.
To directly study the biological effects of VEGF-C in lym-
phedema, we decided to use K14-VEGF-C mice, which
chronically express VEGF-C in the skin, mimicking the
continuous production of VEGF-C in lymphedema. Surpris-
ingly, however, K14-VEGF-C mice exhibited a significantly
exacerbated edema and increased blood vascular leakage
after lymphedema surgery, without major differences in the
vascular density, but with an increased infiltration of
macrophages.
With regard to the potential molecular mechanisms by
which VEGF-C overexpression promoted vascular leakage, it
has previously been found that fully mature VEGF-C
can induce vascular leakage in the skin and mucous
membranes via activation of VEGFR2 (Proulx et al., 2013a;
Saaristo et al., 2002a, 2002b) and that adenoviral
delivery of VEGF-C induced enlargement of blood vessels in
a porcine secondary lymphedema model (Visuri et al., 2015).
On the other hand, K14-sVEGFR3-Ig mice express a
soluble form of the extracellular domain of VEGFR3 in the
skin, scavenging its ligands VEGF-C and VEGF-D. In these
mice, lymphangiogenesis is impaired, whereas the blood
vasculature remains functional (Makinen et al., 2001).
Our findings that lymphedema development was reduced
in K14-sVEGFR3-Ig mice and that there was a reduction of
blood vascularity and diminished vascular leakage,
further supports the hypothesis that high levels of VEGF-C
indeed promote vascular leakage and aggravate
lymphedema. This conclusion is supported by our previous
findings in an experimental, multistep chemical
skin carcinogenesis model, where K14-sVEGFR3-Ig
mice had a reduced angiogenesis and vascular leakage
(Alitalo et al., 2013).
Although VEGF-D serum levels were not found to be
increased after surgery in our mouse tail lymphedema
model, the role of locally increased VEGF-D expression
should still be considered, because of the increased affinity
of the proteolytically processed form toward VEGFR2
(Rissanen et al., 2003; Stacker et al., 1999). In a porcine
model of lymphedema, adenoviral delivery of VEGF-D
resulted in seroma formation due to the induction of
blood vascular permeability (Lahteenvuo et al., 2011), and
VEGF-D levels were increased systemically in primary
lymphedema patients (Fink et al., 2004). These results
indicate a potential role of VEGF-D in edema development,
which cannot be excluded in our model because VEGF-D is
also scavenged by the soluble from of VEGFR3.
Previous work has reported that exogenously administered
VEGF-C can mitigate lymphedema development. Yoon et al.
(2003) reported that application of a naked VEGF-C plasmid
in nude mice ameliorated lymphedema, but later work sug-
gested that lymphedema was actually self-resolving in those
mice because of the absence of CD4þ cells (Zampell et al.,
2012a, 2012b). Local application of VEGF-C in a mouse
tail lymphedema model abrogated tissue damage but led to
only a marginal (0.5e1.0% of volume change) decrease of
edema (Jin da et al., 2009), indicating that the exact role of
exogenously applied VEGF-C still remains unclear.
Despite the promising results of VEGF-C treatment in
promoting lymphatic vessel growth, prolonging lymph node
survival, and architecture maintenance after lymph node
Figure 5. VEGF-C neutralization decreases immune cell infiltrate and blood vascular leakage. (a) Flow cytometry analysis was performed to evaluate the
immune cell infiltration upon lymphedema induction between wild-type and transgenic mice and indicated a trend toward lessened CD45þ and CD11bþ cells
and significantly reduced numbers of CD4þ cells. (b) The effect of sVEGFR3 on blood vascular leakage was evaluated, and leakage was found to be significantly
reduced in the transgenic mice 1 day after surgery. n ¼ 6e8; Student t test, *P < 0.05, **P < 0.01. TG, transgenic; VEGF, vascular endothelial growth factor;
VEGFR, vascular endothelial growth factor receptor; WT, wild type.
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transplantation in lymphedema models (Lahteenvuo et al.,
2011; Tammela et al., 2007), a recent study did not report
beneficial effects of adenoviral VEGF-C delivery on edema
reduction in a porcine secondary lymphedema model (Visuri
et al., 2015). Thus, there are concerns that the blood vascular
adverse effects, which might largely be mediated via activa-
tion of VEGFR2, could counteract the potential activation of
lymphatic vessel function. In this regard, our findings that
VEGFR3 expression was restricted to lymphatic vessels dur-
ing lymphedema development suggest that future therapeutic
approaches might consider the use of the mutated form of
VEGF-C, named VEGF-C156S, that selectively activates
VEGFR3 but not VEGFR2 (Joukov et al., 1998; Saaristo et al.,
2002b).
We and others have recently found that lymphatic vessel
enlargement with lymphatic endothelial cell proliferation is a
characteristic feature of surgically induced lymphedema and
that the dilated lymphatic vessels exhibit impaired drainage
capacity (Gousopoulos et al., 2016b; Rutkowski et al., 2006).
In this regard, our lymphatic drainage assay, showing
decreased lymphatic transport capacity in the K14-VEGF-C
mice, provides corroborating evidence that the exacerbated
edema further impairs lymphatic function. Moreover, there is
experimental evidence that high levels of VEGF-Cmay disrupt
and compromise the lymphatic endothelial barrier in mice,
thereby increasing lymphatic vascular permeability (Tacconi
et al., 2015). Thus, VEGF-C might not only induce leakage of
blood vessels but might also induce hyperpermeable, func-
tionally compromised lymphatic vessels, thereby further
contributing to the pathogenesis of lymphedema.
Lymphedema represents a multistep disease with complex
pathology, where the infiltration of macrophages and local
Figure 6. VEGFR3 expression in
mouse tail skin is restricted to
lymphatic endothelial cells. VEGFR3
expression was examined 2 weeks
after surgery by flow cytometry
analysis using VEGFR3-tdTomato
transgenic reporter mice and by
immunofluorescence co-staining of
tissue sections. (a) TdTomato
fluorescence was detected in CD31þ/
podoplaninþ lymphatic endothelial
cells but not in CD31þ/podoplanine
blood vascular endothelial cells. (b)
TdTomato fluorescence was not
detected in CD3þ T cells and CD11bþ
myeloid cells. Control mice were
VEGFR3-Cre littermates (n ¼ 3). (c)
Double immunofluorescence staining
of mouse tail skin 2 weeks after
surgery for VEGFR3 (green) and LYVE-
1, MECA-32, or CD68 (red) showed
strong VEGFR3 expression in
lymphatic endothelium but not on
blood vessels or CD68þ macrophages
(n ¼ 4). Scale bar ¼ 200 mm. VEGFR,
vascular endothelial growth factor
receptor; WT, wild type.
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production of VEGF-C may represent the beginning of a vi-
cious circle leading to further increased edema formation.
Therefore, the interaction between VEGF-C and the immune
infiltrate, the role of the different immune components, the
exact molecular and cellular mechanisms by which VEGF-C
regulates vascular permeability, and the normalization of
blood vascular leakage as a strategy to control disease pro-
gression represent promising fields for future translational
research.
MATERIALS AND METHODS
Experimental tail model of lymphedema
Lymphedema was surgically induced in the mouse tail as previously
described (Gousopoulos et al., 2016a). Female transgenic mice (on
the FVB background) and their female wild-type littermates had
surgery at the age of 8e12 weeks. Briefly, a 2- to 3-mm circumfer-
ential portion of skin was removed 2 cm distal to the tail base.
Subsequently, the deep collecting lymphatic vessels were identified
and microsurgically excised, with the lateral tail veins maintained
intact. All animal experiments were approved by the Kantonales
Veterina¨ramt Zu¨rich (license number 225/2013).
Tail volume measurements and histology
Tail volume evaluation was performed weekly, using a digital caliper
at 1-cm intervals distally to the surgical excision margin. Tail vol-
umes were calculated using the truncated cone formula
(Gousopoulos et al., 2016a).
Immunofluorescence stains were performed on 7-mmethick cry-
osections of tail skin embedded in optimal cutting temperature
compound (Sakura Finetec, Zoeterwoude, The Netherlands) as pre-
viously reported (Gousopoulos et al., 2016). A detailed description
of the antibodies used is provided in the Supplementary Materials
and Methods online.
Flow cytometry
To evaluate the different immune populations of the lymphedematic
tails, flow cytometry analyses were performed on single cell sus-
pensions obtained from tail skin, as previously described
(Gousopoulos et al., 2016b). The lymphedematic skin was stripped
off the tail and minced, followed by digestion in a mixture of
collagenase II (Sigma, St. Louis, MO) and DNase (Roche, Basel,
Switzerland) in RPMI medium (Gibco, Thermo Fisher Scientific,
Waltham, MA). The single cell suspension was passed through both
70 mm and 40 mm cell strainers and resuspended in FACS buffer. A
detailed description of the antibodies used is provided in the
Supplemental Materials and Methods section.
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